Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Clinical trial NCT06490107 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06490107
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-24
- Primary completion
- 2026-12-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.